Raia Drogasil SA Stock Sao Paulo
Stocks
DROG3
BRDROGACNOR1
Drug Retailers
OTC Markets Traded|
End-of-day quote
Sao Paulo
|
||
| - BRL | - |
|
| 08-06 | Raia Drogasil S.A., Q2 2026 Earnings Call, Aug 05, 2026 | |
| 08-05 | Raia Drogasil S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Market Cap | 31.75B 6.11B 5.36B 5.06B 4.61B 8.63B 585B 8.7B 60.56B 23.46B 299B 22.93B 22.43B 961B | P/E 2026 * |
21.3x | P/E 2027 * | 16x |
|---|---|---|---|---|---|
| Enterprise Value | 39.84B 7.66B 6.72B 6.35B 5.79B 10.83B 734B 10.91B 75.99B 29.43B 375B 28.77B 28.15B 1,206B | EV / Sales 2026 * |
0.88x | EV / Sales 2027 * | 0.79x |
| Free-Float |
73.04% | Yield 2026 * |
2.08% | Yield 2027 * | 2.38% |
Last Transcript: Raia Drogasil SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/01/2025 | |
| Director of Finance/CFO | 63 | 29/04/2013 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 50 | 01/01/2025 | |
| Director/Board Member | - | - | |
Gilberto Lerio
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.00% | -10.23% | +5.07% | -31.55% | 6.21B | |
| -0.49% | -1.01% | -21.45% | +22.57% | 1.21B | |
| +4.39% | +4.21% | +21.49% | +31.19% | 554M | |
| +0.11% | -0.04% | -11.48% | +26.49% | 65.88M | |
| Average | -1.00% | -3.15% | -1.59% | +12.18% | 2.01B | |
| Weighted average by Cap. | -5.95% | -7.53% | +2.06% | -18.59% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 45.4B 8.73B 7.66B 7.24B 6.59B 12.35B 837B 12.43B 86.6B 33.54B 428B 32.79B 32.08B 1,374B | 51.87B 9.98B 8.75B 8.27B 7.53B 14.1B 956B 14.21B 98.94B 38.32B 488B 37.46B 36.65B 1,570B |
| Net income | 1.51B 290M 254M 240M 219M 410M 27.76B 412M 2.87B 1.11B 14.18B 1.09B 1.06B 45.58B | 2.02B 388M 340M 322M 293M 549M 37.18B 552M 3.85B 1.49B 19B 1.46B 1.43B 61.05B |
| Net Debt | 8.09B 1.55B 1.36B 1.29B 1.17B 2.2B 149B 2.21B 15.42B 5.97B 76.14B 5.84B 5.71B 245B | 8.97B 1.73B 1.51B 1.43B 1.3B 2.44B 165B 2.46B 17.11B 6.63B 84.48B 6.48B 6.34B 272B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RADL3 Stock
- DROG3 Stock
Select your edition
All financial news and data tailored to specific country editions
